CAR-T CELLS IN THE TREATMENT OF MULTIPLE MYELOMA: Recent advances and prospects

Immunotherapy with CAR-T cells (Chimeric Antigen Receptor T Cells) has proven to be a revolutionary approach in the treatment of refractory multiple myeloma.Therapies targeting B cell maturation antigen (BCMA) have demonstrated high efficacy, including in high-risk situations.In this context, several CAR-T therapies focused on BCMA are in clinical development, and their clinical approval is imminent.The research carried out was based on a time frame from 2019 to 2023, all in English, which dealt with the management of traditional and pioneering approaches using CAR-T cells in the treatment of multiple myeloma.Therefore, this literary review made use of recognized books in the health area, as well as the Scientific Electronic Library Online (SciELO) and Pubmed platforms as a basis for all scientific articles used in this research.Therefore, the great perception was that recent years were marked by advances in research into chimeric cell therapy for the treatment of multiple myeloma, due to factors such as legal approvals and discoveries of effective working mechanisms, having already indicated impact on the therapeutic options available for multiple myeloma.